AOH1996 Synergizes with Venetoclax to Target Leukemia Stem Cells in AML
核心洞察
AOH1996, a targeted therapy, demonstrates synergistic effects with venetoclax (VEN) in acute myeloid leukemia (搜索) (AML (搜索)) stem cells, enhancing cell death.
The combination of AOH1996 and VEN significantly reduces fatty acid oxidation and oxidative phosphorylation levels in AML (搜索) cells, disrupting their energy metabolism.
In vivo studies show that AOH1996 combined with VEN extends survival in both primary and secondary AML (搜索) mouse models, indicating a potential for improved treatment outcomes.
AOH1996, a novel targeted therapy, has shown promising synergistic effects when combined with venetoclax (VEN) in preclinical models of acute myeloid leukemia (搜索) (AML (搜索)). The research highlights the potential of this combination to target leukemia stem cells (LSCs) by disrupting mitochondrial dynamics and metabolism, leading to enhanced cell death and improved survival rates in vivo.
Synergistic Effects on AML Stem Cells
In vitro studies using primary CD34+CD38- AML (搜索) samples demonstrated that the combination of AOH1996 and VEN resulted in significant synergy, with maximum synergy scores of 26.32 and 22.98 observed in two AML samples. This synergy translates to enhanced cell death compared to either agent alone, suggesting a potent effect on LSC populations.
Impact on Mitochondrial Metabolism
The research further elucidated the mechanism by which AOH1996 and VEN synergize. The combination significantly reduced fatty acid oxidation (FAO) and oxidative phosphorylation (OXPHOS) levels in LSCs. Specifically, the combination impaired mitochondrial respiration, as indicated by reduced oxygen consumption rate (OCR), suggesting that AOH1996 sensitizes AML (搜索) cells to VEN by disrupting their energy metabolism.
In Vivo Efficacy in AML Models
The efficacy of the AOH1996 and VEN combination was also evaluated in vivo using MllPTD/WT/Flt3ITD/ITD AML (搜索) mouse models. Mice treated with the combination of AOH1996 (100 mg/kg, BID, PO) and VEN (100 mg/kg, daily, PO) showed a significant increase in median survival (MS) compared to control, VEN alone, or AOH1996 alone. The median survival was 54 days for the combination group, compared to 34 days for the control and VEN groups, and 43.5 days for the AOH1996 group. Secondary transplants further confirmed the benefit of the combination, with an MS of 49.5 days for the combination group compared to 28, 32.5, and 41 days for the control, VEN, and AOH1996 groups, respectively.
Activity in FLT3-WT PDX AML Model
To assess the broader applicability of the AOH1996 and VEN combination, the researchers also tested its efficacy in a FLT3 (搜索)-WT PDX AML (搜索) model. Similar to the MllPTD/WT/Flt3ITD/ITD model, the combination of AOH1996 and VEN significantly prolonged survival in both primary and secondary transplanted leukemic mice. The median survival in primary recipients was 75.5 days for the combination group, compared to 41, 48, and 55 days for the control, VEN, and AOH1996 groups, respectively. In secondary recipients, the median survival was 76 days for the combination group, compared to 40, 51, and 60 days for the control, VEN, and AOH1996 groups, respectively.
These findings suggest that AOH1996, when combined with venetoclax, represents a promising therapeutic strategy for targeting leukemia (搜索) stem cells and improving outcomes in acute myeloid leukemia, including FLT3 (搜索)-WT AML (搜索).